摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4-二氟环己-1-烯基三氟甲磺酸酯 | 1227068-83-8

中文名称
4,4-二氟环己-1-烯基三氟甲磺酸酯
中文别名
——
英文名称
4,4-difluorocyclohex-1-en-1-yl trifluoromethanesulfonate
英文别名
AD-033-1;4,4-Difluorocyclohex-1-enyl trifluoromethanesulfonate;(4,4-difluorocyclohexen-1-yl) trifluoromethanesulfonate
4,4-二氟环己-1-烯基三氟甲磺酸酯化学式
CAS
1227068-83-8
化学式
C7H7F5O3S
mdl
——
分子量
266.189
InChiKey
GTVRGCYDPDFYLI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    244.0±40.0 °C(Predicted)
  • 密度:
    1.54±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    51.8
  • 氢给体数:
    0
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] COMPOSES DE PYRAZINE COMME INHIBITEURS DE PHOSPHODIESTERASE 10
    申请人:AMGEN INC
    公开号:WO2010057121A1
    公开(公告)日:2010-05-20
    Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    吡嗪化合物、含有它们的组合物以及制备这些化合物的方法。还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法,例如肥胖、非胰岛素依赖型糖尿病、精神分裂症、双相情感障碍、强迫症等。
  • Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta
    申请人:Acadia Pharmaceuticals Inc.
    公开号:EP2554532A1
    公开(公告)日:2013-02-06
    Disclosed herein are novel di-aromatic compounds of the general formula (I): Also pharmaceutical compositions comprising the novel compounds and the use of the novel compounds in treatment and prevention of diseases and disorders related to estrogen receptors are disclosed. Furthermore, methods for treating and preventing diseases and disorders related to estrogen receptors by administration of the novel compounds are disclosed.
    本发明公开了通式(I)的新型二芳香化合物: 还公开了包含该新型化合物的药物组合物,以及新型化合物在治疗和预防与雌激素受体相关的疾病和障碍中的应用。此外,还公开了通过施用新型化合物来治疗和预防与雌激素受体相关的疾病和障碍的方法。
  • [EN] DIPHENYL SUBSTITUTED CYCLOHEXANE DERIVATIVES, USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS BETA<br/>[FR] DÉRIVÉS DE CYCLOHEXANE À SUBSTITUTION DIPHÉNYLE, UTILES EN TANT QUE MODULATEURS DES RÉCEPTEURS BÊTA DES OESTROGÈNES
    申请人:ACADIA PHARM INC
    公开号:WO2013017619A1
    公开(公告)日:2013-02-07
    Disclosed herein are novel di-aromatic compounds of the general formula (I). Also pharmaceutical compositions comprising the novel compounds and the use of the novel compounds in treatment and prevention of diseases and disorders related to estrogen receptors are disclosed. Furthermore, methods for treating and preventing diseases and disorders related to estrogen receptors by administration of the novel compounds are disclosed.
    本发明公开了通式(I)的新型二芳香化合物。还公开了包含该新型化合物的药物组合物,以及该新型化合物在治疗和预防与雌激素受体相关的疾病和障碍中的应用。此外,还公开了通过给予该新型化合物来治疗和预防与雌激素受体相关的疾病和障碍的方法。
  • [EN] 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-AMINO-INDOLE 3-SUBSTITUÉS
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2015198045A1
    公开(公告)日:2015-12-30
    The present invention provides compounds of formula (I) (Formula (I)) and pharmaceutically acceptable salts thereof, wherein Q, X% X4,X5 X6, X7,R1, R2, R3 and R8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.
    本发明提供了公式(I)(公式(I))的化合物及其药用可接受的盐,其中Q,X,X4,X5,X6,X7,R1,R2,R3和R8如说明书中所定义,这些化合物的制备方法,包含它们的药物组合物以及这些化合物在治疗中的用途。
  • Alkenylation and Arylation of Peptides via Ni-Catalyzed Reductive Coupling of α-<i>C</i>-Tosyl Peptides with Csp<sup>2</sup> Triflates/Halides
    作者:Xianghua Tao、Guobin Ma、Yanhong Song、Yunrong Chen、Qun Qian、Deli Sun、Hegui Gong
    DOI:10.1021/acs.orglett.1c02601
    日期:2021.10.1
    A Ni-catalyzed reductive cross-coupling between α-C-tosyl peptides and Csp2 triflates/halides has been developed. This protocol enables the formation of various unnatural di- and tripeptides containing vinyl and aryl side chains, and it expands the applications of Ni-catalyzed reductive cross-coupling in late-stage diversification of peptides.
    已经开发了α-C-甲苯磺酰肽和 Csp 2三氟甲磺酸盐/卤化物之间的 Ni 催化还原交叉偶联。该协议能够形成各种含有乙烯基和芳基侧链的非天然二肽和三肽,并扩展了镍催化还原交叉偶联在肽后期多样化中的应用。
查看更多